Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior participation in designated tolvaptan ADPKD studies (156-04-248, 156-04-249).~* Able to give Informed Consent.~Exclusion Criteria:~* Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods.~* In the opinion of the study investigator or sponsor may present a safety risk.~* Patients who are unlikely to adequately comply with study procedures.~* Patients who at Day 1 have an estimated glomerular filtration rate (GFR) below 30 mL/min or who anticipate renal-replacement therapy within one year of study entry.~* Patients having contraindications to magnetic resonance imaging (MRI) or gadolinium contrast will be eligible but will not be able to participate in MRI.~* Patients taking a diuretic within 1 week of enrollment or likely to need diuretic therapy prior to Month 2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan 45/15 mg/day orally for up to 4 years (Type: EXPERIMENTAL): Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
- Tolvaptan 60/30 mg/day orally for up to 4 years (Type: EXPERIMENTAL): Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).